Sysmex (6869) Q2 2025 earnings summary

Executive summary

• Net sales for the first six months rose 14.0% year-over-year to ¥242.4 billion, with operating profit up 31.6% and profit attributable to owners up 17.2%.

• Growth was driven by strong reagent and maintenance service demand, favorable business in emerging markets, and improved cost of sales ratio.

• Overseas sales accounted for 87.5% of total sales, with robust growth in all major regions.

• Strategic developments included the completion of a new manufacturing base in India and an expanded alliance with QIAGEN in genetic testing.

• Sales increased in all regions and across all major business fields, with notable performance in hematology, hemostasis, and immunochemistry.

Financial highlights

• Net sales: ¥242.4 billion (+14.0% YoY); operating profit: ¥44.5 billion (+31.6% YoY); profit attributable to owners: ¥26.0 billion (+17.2% YoY).

• Gross profit increased to ¥131.3 billion from ¥111.0 billion YoY; operating margin improved to 18.4%.

• Cash and cash equivalents rose to ¥91.7 billion as of September 30, 2024, up ¥16.2 billion from March 31, 2024.

• Net cash provided by operating activities was ¥50.1 billion, up ¥19.5 billion YoY.

• Dividend per share for the year ending March 31, 2025, is forecast at ¥30.00 post-stock split.

Outlook and guidance

• Full-year net sales forecast revised to ¥510.0 billion (+10.5% YoY); operating profit projected at ¥90.0 billion (+14.8% YoY).

• Diagnostics business expected to grow 10.1% YoY, medical robotics business 60.2% YoY.

• Profit attributable to owners expected to reach ¥55.0 billion, with basic EPS of ¥88.21.

• Dividend forecast maintained at ¥30 per share post-stock split, with a payout ratio target of 30%.

• Management notes persistent inflationary risks and ongoing global economic growth, with opportunities in healthcare innovation and digital transformation.